DxPG80 | Biomarker | ECS progastrin

Assist physicians in:

  • Cancer Susceptibility  detection

  • and Follow-up

of cancer patients

DxPG80 IVD test is CE marqued under  the project name cancerREAD. Regulatory revisions are ongoing.

One tool: two applications

1. > Help  Cancer Susceptibility detection

THE GOAL

DxPG80.smart is a new tool to help detect various types of cancer at an early stage. Confirm diagnostic and screening tests.

 Cancer 

Susceptibility  detection

APPROACH

  • Aid to confirm current tests and for early cancer screening

  • An aid to detect cancer progression or relapse

DxPG80.smart is also a confirmatory tool for physicians clinical decision in case the other diagnostic tests give results at the limit of the interpretation. 

DxPG80.smart  should be considered as a clinical decision aid.

2. > Help Follow-up

THE GOAL

An aid to detect cancer progression or relapse. DxPG80.lab is a new tool for patient follow-up. Its goal is to help evaluate a given therapeutic strategy objectively.

Follow-up

of cancer patients

APPROACH

Providing a new tool to help follow up on patients

 

DxPG80.lab is an efficient and inexpensive new tool to help you to monitor treatment efficiency during and after therapy. Simple, reliable, and reproducible, 

DxPG80.lab detects progastrin in a cancer patient’s blood.

 
 
 
 

Simple,

Reliable,

Reproductible 

Solution

PROGASTRIN

A KEY PLAYER IN CANCER DEVELOPMENT AND A SPECIFIC BIOMARKER OF CANCER

Cancer screening is intended to reduce the number of deaths from cancer and, secondarily, to reduce the incidence of cancer. In accomplishing these goals, the ideal cancer screening test is both sensitive and specific, introduces minimal physical and psychological harm to the patient, detects disease at a preclinical phase and screens for a cancer that has a well-defined treatment.

Most tumor markers are made by normal cells as well as by cancer cells; however, they are produced at much higher levels in cancerous conditions.

 

Furthermore, there are some limitations to the use of tumor markers:

  • Noncancerous conditions can cause the levels of certain tumor markers to increase.

  • Not everyone with a particular type of cancer will have a higher level of a tumor marker associated with that cancer.

  • Tumor markers have not been identified for every type of cancer.

  • Low specificity and low sensitivity, especialily at early stages.

 

Finally, no “universal” tumor marker that can detect any type of cancer has been found so far.

 

After ten years of Research & Development, ECS progastrin identified Progastrin as a potential universal tumor marker present in the blood of patient and ECS progastrin developed an ELISA sandwich test able to detect Progastrin in the blood at hight sensitivity and specificity.

1. > GASTRIN

As too much or too little acid can cause disease, gastric acid secretion is tightly regulated by a highly coordinated interaction among a variety of effector, sensory, and feedback pathways. The main hormonal and paracrine stimulants of acid secretion are gastrin, released from pyloric G cells; and histamine, released from oxyntic ECL cells (Schubert et al, current opinion in gastroenterology, 2014). Especially, gastrin is released into the bloodstream when food enters the stomach.

 

Gastrin, mainly present in G cells of the gastric antrum and also in the duodenum, was discovered in 1905 and its structure determined in 1964. Gastrin is synthesized as a 101 amino acid precursor, preprogastrin that, via peptidases and convertases, is processed to Progastrin to yield glycine-extended gastrins (G-Gly) (Dimaline et al, J physiol, 2014) (Fig. 1). Additional processing via peptidyl-glycine α-amidating monooxygenase yields its carboxy terminus amidated forms, mainly G17-NH2 and G34-NH2.

 

Of note Progastrin and Progastrin-releasing peptide (Pro-GRP) are two completely different proteins even though they share the word «Progastrin». Pro-GRP is the precursor for Gastrin-releasing peptide (GRP), a gut hormone that stimulates the release of gastrin in the stomach.

Figure 1

Processing of the products of GAST gene. Numbers in red indicate the processing enzymes:

  1. signal peptidase,

  2. prohormone convertase and carboxypeptidase E,

  3. amidating enzyme

  4. prohormone convertase

Adapted from Stepan et al , American Journal of Physiology (2001)

2. > PROGASTRIN

Other than during digestion, healthy people have no progastrin in their blood*.

 

*In the stomach, cells produce progastrin, which is maturated into gastrin. During digestion 95% of progastrin is released as gastrin from the cell. A very small amount of progastrin is released as progastrin

Progastrin is released from the tumoral cell at the beginning of the tumorigenicity and becomes an early marker**

 

**In the tumour cells, progastrin is not maturated into gastrin. Progastrin is consequently released from the tumoral cell and becomes an early marker. This process is independant of digestion

In 1993, Van Solinge and collaborators showed for the first time a direct link between cancer and progastrin secretion (Van soling et al, Gastroenterology, 1993). Since then, several research groups in the world studied the role of progastrin in cancer.

 

The main results are summarized in the following table:

Activity

Is required for cancer cells proliferation

Modulates the balance proliferation/apoptosis

Is a pro-angiogenic factor in colorectal cancer

Modulates cancer stem cells markers and frequency Modulates the WNT pathway

Modulates the NOTCH pathway

Modulates the PI3K/AKT pathway
 

Publication

Pannequin et al, gastroenterology 2007

Pannequin et al, gastroenterology 2007

Najib et al, Oncogene 2014

Giraud et al, Cancer research 2016

Pannequin et al, gastroenterology 2007

Pannequin et al, Cancer research 2009

Pannequin et al, gastroenterology 2007

3. > WNT PATHWAY

The gene GAST coding for progastrin is a direct target gene of the WNT/ß-catenin oncogenic pathway (Koh et al, JCI, 2000; Pannequin et al Gastroenterology, 2007). The activation of this oncogenic pathway is an early event in cancer development.

Tunable activation of the Wnt/β-catenin target genes

Constituvely activated Wnt/β-catenin pathway leading to continuous expression and secretion of Progastrin

Chronic activation of the WNT/ß-catenin oncogenic pathway occurs in almost all human solid tumors (e.g colorectal, liver, breast, ovarian cancers) and is a central mechanism in cancer biology (Waisberg et al, World J hepatho 2016; Yang et al, Laboratory investigation, 2016).

  • Induction of cellular proliferation and blocking of differentiation leading to primary tumor growth.

  • Induction of epithelial to mesenchymal transition leading to metastasis formation.

  • Regulation of cancer stem cell pathways leading to chemoresistance and relapse.

4. > ELISA sandwitch test

Reliable, Simple, Robust,

Use of common blood sample

DxPG80 IVD test is based on the ELISA technic that is the most reliable and the most routinely used assay to detect biomarker on the blood.

 

ELISA is a test that combines the specificity of antibodies with the sensitivity of simple enzyme assays, by using antibodies coupled to an easily-assayed enzyme. A color change shows the presence of the biomarker.

 
 
 
 
 
 

Secure your future

ECS progastrin SA is a subsidiary of

Progastrine Invest SCSp – Cancer Control Funding Fund

11 côte d'Eich, L1450,

Luxembourg City - Grand Duchy of Luxembourg

Progastrine invest

11 côte d'Eich,

L1450 Luxembourg ville

Grand Duché du Luxembourg

ECS progastrin Lab

Chemin de la Meunière 12

Prilly 1008

Suisse

Progastrin Manufacturing

Chemin de la Meunière 12

Prilly 1008

Suisse

Progastrine et cancers

11 côte d'Eich,

L1450 Luxembourg ville

Grand Duché du Luxembourg

Eurobiodev

2040 avenue du Père Soulas

34000 Montpellier

France

Progastrine Invest SCSp and its subsidiaries

  • focus on innovation in cancer screening, diagnosis and treatment,

  • hold the rights to the first circulating progastrin assay, identified as a new marker associated with cancer. This dosage helps to screen for cancer even at early stages and to monitor therapies,

  • are the holders of the rights to the cancer therapy project with an anti-progastrin antibody.

 

For ethical reasons and out of respect for practitioners, health institutions, populations and regulations in force in all countries where they operate, Progastrine Invest SCSp and its subsidiaries pay extreme attention to the information they publicly provide.

 

The management of Progastrine Invest SCSp, its subsidiaries and their scientific committee would like to remind you that only information published on the official communication media of the group's companies can be considered as confirmed and authorised.

© 2018 ECS progastrin